FolioLanternBeta
PTCTPtc Therapeutics, Inc.

Matthew Klein

Chief Executive Officer, Director at Ptc Therapeutics, Inc., as of Aug 6, 2026Sold $4.2M of stock in the past 12 months: 100% under a disclosed plan.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
384K
shares held after the latest filing, Ptc Therapeutics, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
58K
shares sold, past 12 months
10
days with sales
$917K
largest single day, May 14, 2026
1
company filed for

Share of stake sold at Ptc Therapeutics, Inc. is not shown: most of their shares vested during the period, so a percentage would mislead. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
OctNovDec 2025: $891K under a disclosed planDecJan 2026: $822K under a disclosed planJanFeb 2026: $511K under a disclosed planFebMar 2026: $171K under a disclosed planMarApr 2026: $202K under a disclosed planAprMay 2026: $917K under a disclosed plan$917KMayJunJulAug 2026: $706K under a disclosed planAugSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Ptc Therapeutics, Inc. (PTCT)Chief Executive Officer, DirectorApr 17, 2020Aug 6, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.